Title |
When to Start Antiretroviral Therapy
|
---|---|
Published in |
Current HIV/AIDS Reports, April 2010
|
DOI | 10.1007/s11904-010-0044-6 |
Pubmed ID | |
Authors |
Vivek Jain, Steven G. Deeks |
Abstract |
The question of when to start combination antiretroviral therapy for treatment-naïve patients has always been controversial. This is particularly true in the current era, with major guidelines recommending very different treatment strategies. Despite a lack of clarity regarding the optimal time to begin therapy, there has been a recent shift toward earlier initiation. This more aggressive approach is driven by several observations. First, effective viral suppression with therapy can prevent non-AIDS-related morbidity and mortality. Second, therapy can prevent irreversible harm to the human immune system. Third, therapy may prevent transmission of HIV to others, and thus have a potential public health benefit. For patients who are motivated and willing to initiate early treatment, the collective benefits of early therapy may outweigh the well-documented risks of antiretroviral medications. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Kenya | 1 | 2% |
Unknown | 40 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 17% |
Student > Master | 7 | 17% |
Researcher | 6 | 14% |
Professor > Associate Professor | 4 | 10% |
Student > Bachelor | 3 | 7% |
Other | 7 | 17% |
Unknown | 8 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 45% |
Agricultural and Biological Sciences | 3 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Nursing and Health Professions | 2 | 5% |
Business, Management and Accounting | 2 | 5% |
Other | 7 | 17% |
Unknown | 7 | 17% |